Regeneron(REGN) Prnewswire·2025-01-15 15:34Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Regeneron Pharmaceuticals due to allegations of misleading statements and violations of federal securities laws related to the pricing of its Eylea drug [2][4]. Group 1: Allegations Against Regeneron - The complaint alleges that Regeneron made false and misleading statements regarding credit card fee payments to distributors, which were not disclosed as price concessions [4]. - It is claimed that these undisclosed payments led to inflated reported sales of Eylea and overstated average selling prices (ASP) reported to federal agencies, violating the False Claims Act [4][5]. - The U.S. Department of Justice filed a complaint against Regeneron, alleging that the company failed to report millions in discounts, resulting in inflated Medicare reimbursements [5]. Group 2: Financial Impact - Following the DOJ announcement, Regeneron's stock price fell by 904.70 on April 12, 2024, with unusually heavy trading volume [6]. - On October 31, 2024, Regeneron reported a 3% increase in U.S. net sales for Eylea compared to Q3 2023, with Eylea HD sales of 415 million to 84.59, or 9.2%, to close at 100,000 in Regeneron between November 2, 2023, and October 30, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Regeneron is March 10, 2025 [2][8]. - Any member of the putative class can move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].